Comparison of HER2 Status by Fluorescence in Situ Hybridization and Immunohistochemistry to Predict Benefit From Dose Escalation of Adjuvant Doxorubicin-Based Therapy in Node-Positive Breast Cancer Patients

Dressler, Lynn G.; Berry, Donald A.; Broadwater, Gloria; Cowan, David P.; Cox, Kimberly; Griffin, Stephanie; Miller, Allison N.; Tse, Jessica; Novotny, Debra B.; Persons, Diane L.; Barcos, Maurice; Henderson, I. Craig; Liu, Edison T.; Thor, Ann D.; Budman, D. R.; Muss, Hy; Norton, Larry; Hayes, Daniel F.

doi:10.1200/jco.2005.11.012

Cited by 103 publications

(58 citation statements)

References 22 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…For example, retrospective analyses have shown that anthracycline-based adjuvant therapy is superior to non-anthracycline-based adjuvant chemotherapy in patients with HER2 + tumors, [143][144][145][146][147] and that the dose of doxorubicin may be important in the treatment of tumors that are HER2 + . 148 Prospective evidence of the predictive utility of HER2 status in early-stage [149][150][151][152][153][154] and metastatic breast cancer [155][156][157] is available for trastuzumab-containing therapies. Use of DNA microarray technologies to characterize breast cancer has allowed for the development of classification systems based on gene expression profiles.…”

Section: Estimating Risk Of Relapse or Death And Benefits Of Systemicmentioning

confidence: 99%

Breast Cancer Version 3.2014

Gradishar¹,

Anderson²,

Blair³

et al. 2014

J Natl Compr Canc Netw

Self Cite

175

117

View full text Add to dashboard Cite

Section: Estimating Risk Of Relapse or Death And Benefits Of Systemicmentioning

confidence: 99%

Breast Cancer Version 3.2014

Gradishar¹,

Anderson²,

Blair³

et al. 2014

J Natl Compr Canc Netw

Self Cite

175

117

View full text Add to dashboard Cite

“…Recent studies also describe an association of HER2 amplification with benefit from adjuvant doxorubicinbased chemotherapy (Muss et al 1994, Dressler et al 2005 as well as from paclitaxel administered after four cycles of doxorubicin plus cyclophosphamide . The benefit of HER2-positive patients from anthracyclines appears to be exclusive to the subgroup with HER2-amplified tumors, although some data suggest that this may be due to a co-amplification of the topoisomerase IIa gene (Gennari et al 2008).…”

Section: Her2mentioning

confidence: 99%

Current and emerging biomarkers in breast cancer: prognosis and prediction

Weigel¹,

Dowsett²

2010

Endocrine-Related Cancer

415

296

View full text Add to dashboard Cite

Breast cancer treatment has experienced several changes in the past decades due to the discovery of specific prognostic and predictive biomarkers that enable the application of more individualized therapies to different molecular subgroups. These subgroups show specific differences regarding biological clinical behavior. In addition to the classical clinical prognostic factors of breast cancer, established molecular biomarkers such as estrogen receptor and progesterone receptor have played a significant role in the selection of patients benefiting from endocrine therapy for many years. More recently, the human epidermal growth factor receptor 2 (HER2) has been validated to be not only a prognostic factor, but also a predictor of response to HER2 targeting therapy. The shift toward an earlier diagnosis of breast cancer due to improved imaging methods and screening programs highlights the need for new factors and combinations of biomarkers to quantify the residual risk of patients and to indicate the potential value of additional treatment strategies. The marker of proliferation Ki67 has recently emerged as an important marker due to several applications in neoadjuvant therapy in addition to its moderate prognostic value. With the introduction of high-throughput technologies, numerous multigene signatures have been identified that aim to outperform traditional markers: current prospective clinical trials are seeking evidence for their definitive role in breast cancer. There exist many more factors and approaches that have the potential to become relevant in the near future including the detection of single disseminating and circulating tumor cells in blood and bone marrow as well as of circulating cell-free DNA and microRNA. Careful randomized prospective testing and comparison with existing established factors will be required to select those emerging markers that offer substantial cost-effective benefit and thereby justify their routine use for breast cancer therapy decision-making.

show abstract

“…Moreover, it has been suggested that HER2 overexpression or amplification in breast cancer predicts greater sensitivity to anthracycline-containing chemotherapy (Gennari et al, 2008) and resistance to the CMF regimen (Gusterson et al, 1992). HER2 may also identify patients who are likely to benefit from higher doses of adjuvant chemotherapy (Dressler et al, 2005). The predictive value of HER2 expression regarding the response to taxane-based chemotherapy is considered controversial and the results of the studies have been conflicting, so far .…”

mentioning

confidence: 99%

Evaluation of the prognostic and predictive value of HER family mRNA expression in high-risk early breast cancer: A Hellenic Cooperative Oncology Group (HeCOG) study

et al. 2008

View full text Add to dashboard Cite

The aim of the study was to evaluate the prognostic ability of the transcriptional profiling of the HER family genes in early breast cancer, as well as to investigate the predictive value of HER2 mRNA expression for adjuvant treatment with paclitaxel. RNA was extracted from 268 formalin-fixed paraffin-embedded (FFPE) tumour tissue samples of high-risk breast cancer patients enrolled in the randomised HE10/97 trial, evaluating the effect of dose-dense anthracycline-based sequential adjuvant chemotherapy with or without paclitaxel. The mRNA expression of all four HER family members was assessed by kinetic reverse transcription-polymerase chain reaction (kRT -PCR). The overall concordance between kRT -PCR and IHC/FISH for HER2 status determination was 74%. At a median follow-up of 8 years, multivariate analysis showed that EGFR and HER2 mRNA expression was associated with reduced overall survival (OS). HER3 and HER4 mRNA level had a favourable prognostic value in terms of OS and disease-free survival (DFS), respectively. Adjusting for HER2 mRNA expression, OS and DFS did not differ between treatment groups. These data indicate that EGFR as well as HER2 are prognostic factors of worse clinical outcomes, whereas HER3 and HER4 gene transcription is associated with better prognosis in high-risk early breast cancer. However, HER2 mRNA expression did not predict clinical benefit from paclitaxel. Kinetic RT -PCR represents an alternative method for evaluating the expression of HER family members in FFPE breast carcinomas.

show abstract

Comparison of HER2 Status by Fluorescence in Situ Hybridization and Immunohistochemistry to Predict Benefit From Dose Escalation of Adjuvant Doxorubicin-Based Therapy in Node-Positive Breast Cancer Patients

Cited by 103 publications

References 22 publications

Breast Cancer Version 3.2014

Breast Cancer Version 3.2014

Current and emerging biomarkers in breast cancer: prognosis and prediction

Evaluation of the prognostic and predictive value of HER family mRNA expression in high-risk early breast cancer: A Hellenic Cooperative Oncology Group (HeCOG) study

Contact Info

Product

Resources

About